|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.250 JOD | +1.56% |
|
+1.56% | -1.52% |
| 05-03 | Hayat Pharmaceutical Industries Q1 profit 152,598 dinars | RE |
| 05-02 | Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 30.88M 43.57M 38.32M 35.6M 32.74M 61.4M 4.22B 62.5M 426M 166M 2.06B 164M 160M 7.14B | P/E 2024 |
7.53x | P/E 2025 | 13.6x |
|---|---|---|---|---|---|
| Enterprise Value | 24.79M 34.99M 30.77M 28.59M 26.29M 49.31M 3.39B 50.19M 342M 133M 1.65B 131M 129M 5.73B | EV / Sales 2024 |
1.08x | EV / Sales 2025 | 1.48x |
| Free-Float |
14.49% | Yield 2024 |
8.98% | Yield 2025 | 5.76% |
| 1 day | +1.56% | ||
| 1 week | +1.56% | ||
| Current month | +3.83% | ||
| 1 month | +4.17% | ||
| 3 months | -1.52% | ||
| 6 months | -1.22% | ||
| Current year | -1.52% |
| 1 week | 3.12 | 3.25 | |
| 1 month | 3.11 | 3.25 | |
| Current year | 3.1 | 3.55 | |
| 1 year | 2.9 | 3.55 | |
| 3 years | 2.4 | 3.55 | |
| 5 years | 2.4 | 4.33 | |
| 10 years | 1.72 | 4.33 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 2010-02-07 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 2002-02-16 | |
Raghda Katkhuda
BRD | Director/Board Member | 71 | 2009-11-26 |
| Director/Board Member | 78 | 2010-02-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.56% | +1.56% | +6.21% | +8.33% | 43.57M | ||
| +1.97% | +1.43% | +48.44% | +156.66% | 1,057B | ||
| +1.42% | +3.72% | +53.32% | +52.34% | 624B | ||
| +1.43% | +0.99% | +34.83% | +78.74% | 454B | ||
| +0.14% | +4.88% | +32.21% | +28.15% | 341B | ||
| -1.07% | +1.23% | +35.29% | +39.36% | 297B | ||
| -0.82% | +0.14% | +15.64% | +16.99% | 262B | ||
| -0.49% | -3.21% | -28.58% | -41.95% | 215B | ||
| +1.49% | -0.02% | +20.14% | +58.21% | 201B | ||
| +0.40% | -3.99% | +15.23% | +62.28% | 162B | ||
| Average | -0.05% | +1.11% | +23.28% | +45.91% | 361.4B | |
| Weighted average by Cap. | -0.53% | +1.57% | +34.93% | +75.42% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 16.71M 23.58M 20.74M 19.27M 17.72M 33.23M 2.28B 33.83M 230M 89.86M 1.11B 88.52M 86.61M 3.86B | 17.11M 24.14M 21.23M 19.73M 18.14M 34.02M 2.34B 34.63M 236M 92.01M 1.14B 90.64M 88.68M 3.96B |
| Net income | 3.09M 4.36M 3.83M 3.56M 3.28M 6.14M 422M 6.25M 42.6M 16.62M 206M 16.37M 16.01M 714M | 2.31M 3.26M 2.86M 2.66M 2.45M 4.59M 315M 4.67M 31.82M 12.41M 154M 12.23M 11.96M 534M |
| Net Debt | -5.22M -7.37M -6.48M -6.02M -5.54M -10.38M -713M -10.57M -71.97M -28.07M -348M -27.65M -27.06M -1.21B | -6.08M -8.58M -7.55M -7.01M -6.45M -12.09M -831M -12.31M -83.85M -32.7M -405M -32.22M -31.52M -1.41B |
Employees
246
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- HPIC Stock
Select your edition
All financial news and data tailored to specific country editions
















